Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles
We report here that both EWS::FLI1 and ERG bind and transcriptionally activate GGAA-rich pericentromeric heterochromatin. The respective pathogen-like HSAT2 and HSAT3 RNAs, together with LINE, SINE, ERV and other repeat transcripts, are expressed in EwS and PCa tumors, secreted in extracellular vesicles (EVs) and are highly elevated in plasma of EwS patients with metastatic disease. High HSAT2,3 levels in EWS::FLI1 or ERG expressing cells and tumors were associated with induction of G2/M checkpoint, mitotic spindle and DNA damage programs. These programs were also activated in EwS EV-treated fibroblasts, coincident with ac...
Source: Clinical Prostate Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Peter Ruzanov Valentina Evdokimova Manideep C Pachva Alon Minkovich Zhenbo Zhang Sofya Langman Hendrik Gassmann Uwe Thiel Marija Orlic-Milacic Syed H Zaidi Vanya Peltekova Lawrence E Heisler Manju Sharma Michael E Cox Trevor D McKee Mark Zaidi Eve Lapoubl Source Type: research
Heterochronous multiple primary prostate cancer and lymphoma: A case report
CONCLUSION: Although rare, the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding.PMID:38524523 | PMC:PMC10955537 | DOI:10.12998/wjcc.v12.i7.1333 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Jin-Long Liang Yu-Qing Bu Li-Li Peng Hong-Zhen Zhang Source Type: research
Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX
CONCLUSIONS: Our analysis indicates a growing trend in the utilization of tissue-based genomic testing for PCa. Nevertheless, they are utilized in less than 2% of PCa patients, whether at initial diagnosis or after surgical treatment. Although it is anticipated that their use may increase as more scientific evidence becomes available, their role requires further elucidation.PMID:38525718 | PMC:PMC10961791 | DOI:10.3390/clinpract14020039 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Eugenio Bologna Francesco Ditonno Leslie Claire Licari Antonio Franco Celeste Manfredi Spencer Mossack Savio Domenico Pandolfo Cosimo De Nunzio Giuseppe Simone Costantino Leonardo Giorgio Franco Source Type: research
Heterochronous multiple primary prostate cancer and lymphoma: A case report
CONCLUSION: Although rare, the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding.PMID:38524523 | PMC:PMC10955537 | DOI:10.12998/wjcc.v12.i7.1333 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Jin-Long Liang Yu-Qing Bu Li-Li Peng Hong-Zhen Zhang Source Type: research
Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX
CONCLUSIONS: Our analysis indicates a growing trend in the utilization of tissue-based genomic testing for PCa. Nevertheless, they are utilized in less than 2% of PCa patients, whether at initial diagnosis or after surgical treatment. Although it is anticipated that their use may increase as more scientific evidence becomes available, their role requires further elucidation.PMID:38525718 | PMC:PMC10961791 | DOI:10.3390/clinpract14020039 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Eugenio Bologna Francesco Ditonno Leslie Claire Licari Antonio Franco Celeste Manfredi Spencer Mossack Savio Domenico Pandolfo Cosimo De Nunzio Giuseppe Simone Costantino Leonardo Giorgio Franco Source Type: research
Electrochemical immunosensing of tumor markers
Clin Chim Acta. 2024 Mar 21;557:117882. doi: 10.1016/j.cca.2024.117882. Online ahead of print.ABSTRACTThe rising incidence and mortality rates of cancer have led to a growing need for precise and prompt early diagnostic approaches to effectively combat this disease. However, traditional methods employed for detecting tumor cells, such as histopathological and immunological techniques, are often associated with complex procedures, high analytical expenses, elevated false positive rates, and a dependence on experienced personnel. Tracking tumor markers is recognized as one of the most effective approaches for early detection...
Source: Clinical Prostate Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Venkata Narayana Palakollu Y Veera Manohara Reddy Mehdihasan I Shekh S V Prabhakar Vattikuti Jaesool Shim Rajshekhar Karpoormath Source Type: research
Federal and State Policy Issues Affecting Lesbian, Gay, Bisexual, Transgender, and Queer Older Adults
Clin Geriatr Med. 2024 May;40(2):357-366. doi: 10.1016/j.cger.2023.10.007. Epub 2023 Nov 18.ABSTRACTAnti-lesbian, gay, bisexual, transgender, and queer (LGBTQ) + discrimination is widespread, harming the health of LGBTQ + people and constituting a barrier to care. This contributes to higher rates of poverty among LGBTQ + people, especially among people of color, and lower insurance coverage rates. The Affordable Care Act's expansion of insurance access has reduced uninsurance rates among LGBT people and people living with human immunodeficienc virus (HIV). Systemic improvements in culturally responsive health care have occ...
Source: Clinical Prostate Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Sean R Cahill Source Type: research
Electrochemical immunosensing of tumor markers
Clin Chim Acta. 2024 Mar 21:117882. doi: 10.1016/j.cca.2024.117882. Online ahead of print.ABSTRACTThe rising incidence and mortality rates of cancer have led to a growing need for precise and prompt early diagnostic approaches to effectively combat this disease. However, traditional methods employed for detecting tumor cells, such as histopathological and immunological techniques, are often associated with complex procedures, high analytical expenses, elevated false positive rates, and a dependence on experienced personnel. Tracking tumor markers is recognized as one of the most effective approaches for early detection and...
Source: Clinical Prostate Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Venkata Narayana Palakollu Y Veera Manohara Reddy Mehdihasan I Shekh S V Prabhakar Vattikuti Jaesool Shim Rajshekhar Karpoormath Source Type: research
Federal and State Policy Issues Affecting Lesbian, Gay, Bisexual, Transgender, and Queer Older Adults
Clin Geriatr Med. 2024 May;40(2):357-366. doi: 10.1016/j.cger.2023.10.007. Epub 2023 Nov 18.ABSTRACTAnti-lesbian, gay, bisexual, transgender, and queer (LGBTQ) + discrimination is widespread, harming the health of LGBTQ + people and constituting a barrier to care. This contributes to higher rates of poverty among LGBTQ + people, especially among people of color, and lower insurance coverage rates. The Affordable Care Act's expansion of insurance access has reduced uninsurance rates among LGBT people and people living with human immunodeficienc virus (HIV). Systemic improvements in culturally responsive health care have occ...
Source: Clinical Prostate Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Sean R Cahill Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Clinical Prostate Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients
CONCLUSIONS: The combination of docetaxel/ADT and synthetic lycopene has low toxicity and favourable pharmacokinetics. The effects of lycopene on biomarkers provide additional support for the toxicity-dependent MTD definition.HIGHLIGHTS: The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration w...
Source: Clinical Prostate Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Michael B Lilly Chunli Wu Yu Ke Wen-Pin Chen Adam C Soloff Kent Armeson Noriko N Yokoyama Xiaotian Li Liankun Song Ying Yuan Christine E McLaren Xiaolin Zi Source Type: research
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1
CONCLUSION: Abemaciclib monotherapy was well tolerated and showed clinical activity in this heavily pretreated population, nearly half with visceral metastases. This study is considered preliminary proof-of-concept and designates CDK4/6 as a valid therapeutic target in prostate cancer.PMID:38512117 | DOI:10.1158/1078-0432.CCR-23-3436 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Neeraj Agarwal Daniel Castellano Teresa Alonso-Gordoa Jose Angel Arranz Arija Emeline Colomba Gwenaelle Gravis Loic Mourey Stephane Oudard Aude Fl échon Macarena Gonzalez Pablo M Maroto Michael T Schweizer Enrique Gallardo Erica Johnston Arjun Balar Nadi Source Type: research
Cancer Treatment Disparities in People With HIV in the United States, 2001-2019
CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.PMID:38513161 | DOI:10.1200/JCO.23.02366 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Jennifer K McGee-Avila Gita Suneja Eric A Engels Anne F Rositch Marie-Josephe Horner Qianlai Luo Meredith S Shiels Jessica Y Islam Source Type: research
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1
CONCLUSION: Abemaciclib monotherapy was well tolerated and showed clinical activity in this heavily pretreated population, nearly half with visceral metastases. This study is considered preliminary proof-of-concept and designates CDK4/6 as a valid therapeutic target in prostate cancer.PMID:38512117 | DOI:10.1158/1078-0432.CCR-23-3436 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Neeraj Agarwal Daniel Castellano Teresa Alonso-Gordoa Jose Angel Arranz Arija Emeline Colomba Gwenaelle Gravis Loic Mourey Stephane Oudard Aude Fl échon Macarena Gonzalez Pablo M Maroto Michael T Schweizer Enrique Gallardo Erica Johnston Arjun Balar Nadi Source Type: research
Cancer Treatment Disparities in People With HIV in the United States, 2001-2019
CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.PMID:38513161 | DOI:10.1200/JCO.23.02366 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Jennifer K McGee-Avila Gita Suneja Eric A Engels Anne F Rositch Marie-Josephe Horner Qianlai Luo Meredith S Shiels Jessica Y Islam Source Type: research
